Biotech Acquisition Company is a blank check company, incorporated as a Cayman Islands exempted company, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. BAC believes that a partnership with target companies focused in the healthcare sector will complement the background and expertise of SPRIM Global Investments (a global investment firm in the life sciences and healthcare industries), an affiliate of and the management team behind BAC. BAC is led by Dr. Michael Shleifer, its CEO and chairman. The Class A Ordinary Shares and Warrants of BAC trade on the NASDAQ Capital Market under the symbols “BIOT” and “BIOTW,” respectively.

Biotech Acquisition Company raised $230mm in its initial public offering on January 28, 2021.

Cautionary Note Concerning Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements,” including with respect to the anticipated use of the net proceeds from the Company’s initial public offering. No assurance can be given that the net proceeds will be used as indicated. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s prospectus relating to the offering, which is filed with the U.S. Securities and Exchange Commission (“SEC”). Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update its forward-looking statements, except as required by law.

No Offer or Solicitation

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act of 1933, as amended.